Peptide Fragments

Name
Peptide Fragments
Accession Number
DBCAT001722
Description

Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques.

Drugs
DrugDrug Description
AbciximabA monoclonal anti-glycoprotein IIb/IIIa receptor antibody used to prevent thrombosis during percutaneous coronary intervention.
PexelizumabFor the treatment of inflammation during cardiac surgery.
PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
CaplacizumabA von Willebrand factor (vWF)-directed antibody fragment used to treat acquired thrombotic thrombocytopenic purpura (aTTP).
Certolizumab pegolA tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
DulaglutideA GLP-1 agonist used to manage type 2 diabetes mellitus.
LampalizumabLampalizumab has been used in trials studying the treatment of Geographic Atrophy.
VobarilizumabVobarilizumab is under investigation in clinical trial NCT02101073 (ALX-0061 Phase I Bioavailability Study in Healthy Volunteers).
DalanterceptDalantercept is under investigation in clinical trial NCT00996957 (Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma).
IpafriceptIpafricept is under investigation in clinical trial NCT01608867 (A Dose Escalation Study of OMP-54F28 in Subjects With Solid Tumors).
EnfuvirtideAn HIV-1 gp41 fusion inhibitor used in patients experiencing HIV-1 replication who are already being treated with other anti-retrovirals.
Eftrenonacog alfaA recombinant Factor IX used to treat and prevent bleeding in hemophilia B.
LuspaterceptAn erythroid maturation agent used to treat anemia secondary to beta thalassemia in patients requiring regular red blood cell transfusions.
GancotamabGancotamab is under investigation in clinical trial NCT02213744 (MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients).
Drugs & Drug Targets
DrugTargetType
AbciximabIntegrin beta-3target
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
AbciximabIntegrin alpha-IIbtarget
AbciximabVitronectintarget
PRO-542Free fatty acid receptor 4target
Caplacizumabvon Willebrand factortarget
Certolizumab pegolTumor necrosis factortarget
Certolizumab pegolAlcohol dehydrogenase [NADP(+)]enzyme
DulaglutideGlucagon-like peptide 1 receptortarget
EnfuvirtideEnvelope glycoproteintarget
EnfuvirtideCytochrome P450 2C19enzyme
EnfuvirtideCytochrome P450 2E1enzyme